A real-world study confirms survival outcomes of atezolizumab plus chemotherapy in extensive-stage small cell lung cancer. Similar survival outcomes of a real-world study of a first-line treatment regimen were demonstrated in the phase 3 IMpower133...
TUESDAY, Oct. 1, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic...
Clinicians should account for the time of day when performing asthma diagnostic tests, as most patients experience more symptoms overnight and in the morning.
In the phase 1/2 ALKOVE-1 trial, the ALK-selective tyrosine kinase inhibitor (TKI) NVL-655 demonstrated promising safety and clinical activity in patients with heavily pre-treated ALK-positive non-small cell lung cancer (NSCLC). NVL-655 is a new and potent,...
The following is a summary of ”High burden of Ileus and Pneumonia in Clozapine-treated individuals With Schizophrenia: A Finnish 25-year follow-up register study,” published in the September 2024 issue of Psychiatry by Partanen et al. Researchers conducted a...
Survival in NSCLC improved with guideline-concordant care in lung cancer, and several factors can be addressed to reach more patients with such care.
TUESDAY, Oct. 1, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic...
Clinicians should account for the time of day when performing asthma diagnostic tests, as most patients experience more symptoms overnight and in the morning.
In the phase 1/2 ALKOVE-1 trial, the ALK-selective tyrosine kinase inhibitor (TKI) NVL-655 demonstrated promising safety and clinical activity in patients with heavily pre-treated ALK-positive non-small cell lung cancer (NSCLC). NVL-655 is a new and potent,...
The following is a summary of ”High burden of Ileus and Pneumonia in Clozapine-treated individuals With Schizophrenia: A Finnish 25-year follow-up register study,” published in the September 2024 issue of Psychiatry by Partanen et al. Researchers conducted a...
Survival in NSCLC improved with guideline-concordant care in lung cancer, and several factors can be addressed to reach more patients with such care.
A collection of feature articles, study abstracts, and other resources all focused COPD.
The latest news from ASCO 2024 focused on eNSCLC including abstracts, features, and helpful conference information.
Physician’s Weekly-created content featuring key opinion leaders sharing their perspectives on COPD and asthma from different vantage points.
Yvette C. Terrie, RPh, shares insights into addressing non-adherence and motivating patients to adhere to medication recommendations and health practices.
Patients have easy access to health information, so doctors must enhance efforts involving helping patients understand their conditions and treatment options.
In this medical fiction, a pampered heir's anti-antibiotic crusade ends after an encounter with a bear cub renders him a victim of his own misguided beliefs.
This course discusses why patients with COPD who live in urban areas and in disadvantaged neighborhoods have significantly elevated all-cause mortality, suggesting that social determinants of health may impact COPD outcomes.
Medical cartoon about ICD-10 codes raining down on the medical community during ICD-10-CM update season.
2025 ICD-10-CM updates include new codes, code deletions and revisions, and a conversion table that identifies inactive codes and their replacements.
Although a patient's request for a second opinion can make a physician question the patient’s trust level, physicians should consider supporting that desire.
Working in a concierge healthcare system allows doctors to reclaim their primary role in patient care and reconnect with meaning in their practice of medicine.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
